tiprankstipranks
Trending News
More News >
Silexion Therapeutics Corp (SLXN)
:SLXN
US Market

Silexion Therapeutics (SLXN) Ratios

Compare
212 Followers

Silexion Therapeutics Ratios

SLXN's free cash flow for Q3 2025 was $―. For the 2025 fiscal year, SLXN's free cash flow was decreased by $ and operating cash flow was $―. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
2.44 2.27 5.49--
Quick Ratio
2.44 2.27 5.49--
Cash Ratio
1.61 2.09 5.13--
Solvency Ratio
-3.14 -0.28 -0.19--
Operating Cash Flow Ratio
-4.90 -2.06 -2.07--
Short-Term Operating Cash Flow Coverage
0.00 0.00 0.00--
Net Current Asset Value
$ -440.00K$ -12.33M$ -7.57M--
Leverage Ratios
Debt-to-Assets Ratio
0.64 0.03 0.03--
Debt-to-Equity Ratio
30.82 -0.01 -0.03--
Debt-to-Capital Ratio
0.97 -0.01 -0.03--
Long-Term Debt-to-Capital Ratio
0.96 0.00 0.00--
Financial Leverage Ratio
48.31 -0.34 -0.88--
Debt Service Coverage Ratio
-294.05 -518.67 -45.02--
Interest Coverage Ratio
-227.38 -520.11 -45.41--
Debt to Market Cap
1.85 0.00 0.00--
Interest Debt Per Share
6.49 0.02 0.04--
Net Debt to EBITDA
-0.01 0.95 2.10--
Profitability Margins
Gross Profit Margin
0.00%0.00%0.00%--
EBIT Margin
0.00%0.00%0.00%--
EBITDA Margin
0.00%0.00%0.00%--
Operating Profit Margin
0.00%0.00%0.00%--
Pretax Profit Margin
0.00%0.00%0.00%--
Net Profit Margin
0.00%0.00%0.00%--
Continuous Operations Profit Margin
0.00%0.00%0.00%--
Net Income Per EBT
100.03%97.36%92.81%--
EBT Per EBIT
128.62%108.44%89.74%--
Return on Assets (ROA)
-307.83%-94.03%-34.45%--
Return on Equity (ROE)
1217.67%31.93%30.15%--
Return on Capital Employed (ROCE)
-380.31%-152.97%-49.98%--
Return on Invested Capital (ROIC)
-363.40%-148.50%-49.59%--
Return on Tangible Assets
-307.83%-94.03%-34.45%--
Earnings Yield
-1003.02%-3.45%-2.25%--
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00--
Payables Turnover
0.04 0.00 0.00--
Inventory Turnover
0.00 0.00 0.00--
Fixed Asset Turnover
0.00 0.00 0.00--
Asset Turnover
0.00 0.00 0.00--
Working Capital Turnover Ratio
0.00 0.00 0.00--
Cash Conversion Cycle
-8.71K 0.00 0.00--
Days of Sales Outstanding
0.00 0.00 0.00--
Days of Inventory Outstanding
0.00 0.00 0.00--
Days of Payables Outstanding
8.71K 0.00 0.00--
Operating Cycle
0.00 0.00 0.00--
Cash Flow Ratios
Operating Cash Flow Per Share
-18.19 -0.56 -0.41--
Free Cash Flow Per Share
-18.23 -0.56 -0.41--
CapEx Per Share
0.04 <0.01 <0.01--
Free Cash Flow to Operating Cash Flow
1.00 1.00 1.01--
Dividend Paid and CapEx Coverage Ratio
-458.22 -377.42 -83.38--
Capital Expenditure Coverage Ratio
-458.22 -377.42 -83.38--
Operating Cash Flow Coverage Ratio
-2.85 -26.49 -12.31--
Operating Cash Flow to Sales Ratio
0.00 0.00 0.00--
Free Cash Flow Yield
-613.30%-3.17%-2.36%--
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-0.10 -28.95 -44.50--
Price-to-Sales (P/S) Ratio
0.00 0.00 0.00--
Price-to-Book (P/B) Ratio
14.83 -9.24 -13.41--
Price-to-Free Cash Flow (P/FCF) Ratio
-0.16 -31.51 -42.39--
Price-to-Operating Cash Flow Ratio
-0.17 -31.59 -42.90--
Price-to-Earnings Growth (PEG) Ratio
>-0.01 -0.51 0.00--
Price-to-Fair Value
14.83 -9.24 -13.41--
Enterprise Value Multiple
-0.11 -29.91 -35.52--
Enterprise Value
1.95M 138.64M 135.07M--
EV to EBITDA
-0.11 -29.91 -35.52--
EV to Sales
0.00 0.00 0.00--
EV to Free Cash Flow
-0.19 -30.53 -40.02--
EV to Operating Cash Flow
-0.19 -30.61 -40.50--
Tangible Book Value Per Share
0.21 -1.48 -0.87--
Shareholders’ Equity Per Share
0.21 -1.90 -1.31--
Tax and Other Ratios
Effective Tax Rate
>-0.01 >-0.01 >-0.01--
Revenue Per Share
0.00 0.00 0.00--
Net Income Per Share
-30.79 -0.61 -0.39--
Tax Burden
1.00 0.97 0.93--
Interest Burden
0.99 1.08 0.90--
Research & Development to Revenue
0.00 0.00 0.00--
SG&A to Revenue
0.00 0.00 0.00--
Stock-Based Compensation to Revenue
0.00 0.00 0.00--
Income Quality
0.59 0.89 0.96--
Currency in USD